• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

    12/13/22 10:00:00 AM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email

     Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting

    BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events

    BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). These data will be presented (Abstract #LBA-6) during the late-breaking session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans and simultaneously published in The New England Journal of Medicine. The paper's lead author Jennifer Brown, M.D., Ph.D., Director, CLL Center at Dana-Farber Cancer Institute will present these data.

    Dr. Brown noted that "PFS is the gold standard for measuring efficacy in CLL clinical trials. The ALPINE data showing superior efficacy and consistent benefit across patient subgroups including patients with high-risk del(17p)/TP53, along with a favorable cardiovascular safety profile, provide compelling evidence for BRUKINSA as a practice-changing Bruton's tyrosine kinase (BTK) inhibitor for patients with CLL."

    "BRUKINSA was specifically designed to maximize BTK occupancy and minimize off-target effects. Our clinical development programs were intended to test for a differentiated efficacy and safety profile," said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. "We believe the ALPINE PFS data and cardiac safety results for BRUKINSA, including an absence of cardiac death, demonstrate a meaningful advance in outcomes for patients with CLL."

    In this final analysis, BRUKINSA achieved superior PFS over ibrutinib (HR: 0.65 [95% CI, 0.49-0.86] p=0.0024, for both Independent Review Committee [IRC] and investigator). At 24 months, the investigator-assessed PFS rates were 78.4% for BRUKINSA compared to 65.9% with ibrutinib. The PFS benefit was observed across all major subgroups, including high-risk del(17p)/TP53 (HR: 0.52; [95% CI, 0.30-0.88]), as assessed by IRC. BRUKINSA also demonstrated higher overall response rate (ORR), with a response rate of 80.4% versus 72.9% (two-sided p=0.0264), as assessed by IRC.

    BRUKINSA was generally well-tolerated with fewer adverse events leading to treatment discontinuation compared with ibrutinib (15.4% vs. 22.2%). There was a lower rate of cardiac disorders for BRUKINSA compared with ibrutinib (21.3% vs 29.6%), and cardiac disorders leading to treatment discontinuation occurred in one BRUKINSA patient versus 14 ibrutinib patients (0.3% vs. 4.3%). No patient receiving BRUKINSA died due to a cardiac adverse event; six patients receiving ibrutinib experienced a fatal cardiac adverse event (0% vs. 1.9%). The most commonly reported treatment emergent adverse events (≥20%) with BRUKINSA and ibrutinib were diarrhea (16.0% vs. 24.1%), hypertension (14.8% vs. 11.1%), neutropenia (22.8% vs. 18.2%), COVID-19 (23.1% vs. 17.9%), and upper respiratory tract infection (21.0% vs. 14.2%).

    CLL is the most common type of leukemia in adults, accounting for about one-quarter of new cases of leukemia in the United States.1 The condition is characterized by consecutive relapses, with response to therapy ultimately determining clinical benefit, including survival.

    BeiGene's sNDA for BRUKINSA in CLL is currently under review with the FDA and has a target action date of January 20, 2023.

    Investor Events

    • Tuesday, December 13, 2022 - BeiGene will host a webcast and conference call following the ALPINE late-breaker presentation at 2:00 p.m. CST. BeiGene senior management along with invited medical experts will review the presented data and join for a Q&A panel.
      • Dial in: 855-303-0072; Passcode: 306575
    • Tuesday, December 13, 2022 - BeiGene will host a webcast in Chinese at 6:00 p.m. CST/December 14, 2022 8:00 a.m. China time to capture company presentations at ASH. BeiGene senior management will review highlights of the presented data.
      • Dial in: +86 10 8783 3177 or +86 10 5387 6330; Passcode: 03233799

    These events can be accessed live from the Investors section of BeiGene's website at http://ir.beigene.com, http://hkexir.beigene.com or https://sseir.beigene.com. Archived replays will be posted for 90 days following both events.

    About ALPINE

    ALPINE is a randomized, global Phase 3 trial (NCT03734016) comparing BRUKINSA against ibrutinib in previously treated patients with relapsed or refractory chronic lymphocytic leukemia CLL or SLL. In the trial, a total of 652 patients across Europe (60%), the United States (17%), China (14%), New Zealand and Australia (9%) were randomized into two arms, with the first receiving BRUKINSA (160 mg orally twice daily) and the second receiving ibrutinib (420 mg orally once daily) until disease progression or unacceptable toxicity.

    The primary endpoint of overall response rate (ORR), defined by pre-specified non-inferiority of BRUKINSA versus ibrutinib, was assessed by investigator and IRC using the modified 2008 iwCLL guidelines, with modification for treatment-related lymphocytosis for patients with CLL, and per Lugano Classification for non-Hodgkin's lymphoma for patients with SLL. There was pre-specified hierarchical testing of non-inferiority followed by superiority in ORR as assessed by investigator and IRC. Key secondary endpoints include PFS and event rate of atrial fibrillation or flutter; other secondary endpoints include duration of response, overall survival, and incidence of adverse events.

    Interim study results from ALPINE were published online in Journal of Clinical Oncology in November 2022 (DOI: 10.1200/JCO.22.00510).

    About BRUKINSA

    BRUKINSA is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. BRUKINSA was specifically designed to deliver targeted and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

    BRUKINSA is supported by a broad clinical program which includes more than 4,700 subjects in 35 trials in more than 30 geographies. To date, BRUKINSA is approved in more than 60 markets, including the United States, China, the European Union, Great Britain, Canada, Australia, South Korea, Switzerland, and additional international markets.

    About BeiGene

    BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential implications of the Phase 3 ALPINE trial data for patients, the timing of regulatory review and potential approval of BRUKINSA as a new treatment option for patients with CLL, the potential for BRUKINSA to provide clinical benefit to patients with CLL, BeiGene's plan for the advancement, and anticipated clinical development, regulatory milestones and commercialization of BRUKINSA, and BeiGene's plans, commitments, aspirations, and goals under the heading "About BeiGene." Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; and the impact of the COVID-19 pandemic on BeiGene's clinical development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

    IMBRUVICA® is a registered trademark of Pharmacyclics LLC and Janssen Biotech, Inc.

    References

    [1] National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia —Chronic Lymphocytic Leukemia (CLL). Accessed October 4, 2021. https://seer.cancer.gov/statfacts/html/clyl.html

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005484/en/

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE

    DatePrice TargetRatingAnalyst
    12/3/2024$300.00Overweight
    Morgan Stanley
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    2/6/2024$185.00Overweight
    JP Morgan
    9/12/2023$259.00Outperform
    Macquarie
    8/17/2023$287.00Buy
    Jefferies
    7/17/2023$275.00Buy
    Citigroup
    6/30/2023$335.00 → $196.00Outperform → Mkt Perform
    Bernstein
    1/12/2023$308.00Buy
    Daiwa Securities
    More analyst ratings

    $BGNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

      Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lu

      3/31/25 6:00:00 AM ET
      $BGNE
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

      New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors e

      12/27/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. "As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative h

      12/23/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/10/24 9:30:34 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

      12/4/24 4:05:33 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

      SC 13D/A - BeiGene, Ltd. (0001651308) (Filed by)

      10/31/24 6:29:37 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    SEC Filings

    See more
    • BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/23/24 6:05:32 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/10/24 6:02:43 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BeiGene Ltd.

      144 - BeiGene, Ltd. (0001651308) (Subject)

      12/9/24 9:48:25 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial

      9/26/24 6:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Updates to Commercial Leadership Team

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov

      9/9/24 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Oyler John exercised 1,300,000 units of Ordinary Shares at a strike of $0.50, increasing direct ownership by 77% to 2,978,833 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/17/24 5:02:43 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair, Scientific Advisory Brd Wang Xiaodong sold $7,805,106 worth of American Depositary Shares (41,760 units at $186.90) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/12/24 5:18:09 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Bros. Advisors Lp sold $194,200,043 worth of American Depositary Shares (1,037,017 units at $187.27) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      12/10/24 9:25:48 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Financials

    Live finance-specific insights

    See more
    • BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

      BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam

      7/10/23 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

       Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic

      12/13/22 10:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021

      BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company

      8/16/21 7:00:00 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on BeiGene with a new price target

      Morgan Stanley resumed coverage of BeiGene with a rating of Overweight and set a new price target of $300.00

      12/3/24 8:35:59 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on BeiGene with a new price target

      JMP Securities initiated coverage of BeiGene with a rating of Mkt Outperform and set a new price target of $288.00

      9/18/24 7:31:13 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on BeiGene with a new price target

      JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $185.00

      2/6/24 7:59:18 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care